A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Latest Information Update: 13 May 2025
At a glance
- Drugs JAB 23E73 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jacobio Pharmaceuticals
Most Recent Events
- 13 May 2025 New trial record